Drug Type Therapeutic vaccine |
Synonyms CIMAv, CimaVax EGF, CIMAvax Epidermal Growth Factor Vaccine + [15] |
Target |
Mechanism EGF inhibitors(Epidermal growth factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CU (01 Jun 2008), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Epidermal growth factor cancer vaccine(Center of Molecular Immunology) | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Colorectal Cancer | CU | - | 01 Jun 2008 |
Non-Small Cell Lung Cancer | CU | - | 01 Jun 2008 |
Prostatic Cancer | CU | - | 01 Jun 2008 |
Stomach Cancer | CU | - | 01 Jun 2008 |
CIMAvax-EGF (NEWS) Manual | Not Applicable | - | CIMAvax-EGF | vkmtshkyyi(uwbrdvdcgt) = bdsswicqie layrtwtpji (odjjajbgvr ) | Positive | 05 Dec 2023 | |
placebo | vkmtshkyyi(uwbrdvdcgt) = ozdprcptpb layrtwtpji (odjjajbgvr ) | ||||||
NEWS Manual | Not Applicable | 405 | CIMAvax-EGF (肺鳞癌) | eyuhnuoedm(ypktromite) = oqxriallgj ewqfdglqbn (vnmoyfjhxl ) | Positive | 28 Nov 2023 | |
最佳支持治疗 + 肺鳞癌 | eyuhnuoedm(ypktromite) = iyydwkldll ewqfdglqbn (vnmoyfjhxl ) | ||||||
NCT02955290 (ASCO2023) Manual | Phase 2 | Advanced Lung Non-Small Cell Carcinoma Second line | 21 | iraedivuzo(ewdydtwedg) = vefawckytk lybcihyakd (lsyfrrqipa, 14 - 45) View more | Positive | 31 May 2023 | |
( PD-L1 expression ≥1% ) | iraedivuzo(ewdydtwedg) = xzhexapnnv lybcihyakd (lsyfrrqipa, 12 - 63) View more | ||||||
Phase 4 | 741 | (EGF concentrations <870 pg/mL) | imizamwbog(ssfbdyppjc) = xtdihgwjfk rnmbthseig (vzosagilkc ) View more | - | 10 Sep 2022 | ||
(EGF concentrations ≥870 pg/mL) | imizamwbog(ssfbdyppjc) = onutftspow rnmbthseig (vzosagilkc ) View more | ||||||
NCT02955290 (pubmed) Manual | Phase 1/2 | 13 | nivolumab+CIMAvax-EGF | vilkskehxq(vhjmcrvbbi) = dpqevyqjkc ffbhbdlusp (bnxbnezkxc ) View more | Positive | 03 Aug 2022 | |
Phase 1 | EGFR positive non-small cell lung cancer EGFR Positive | 9 | EGFR-specific CAR-T cells | wkwfsrwpng(niupwggnfv) = fever kupbembpps (bbhbkhatke ) View more | Positive | 01 Dec 2021 | |
Phase 1 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 23 | afatinib+anti-EGF vaccination | kcfpsvlwxg(jpioowswqw) = no SAES related to anti-EGF vaccination were reported qwbfoxtbdn (xtqbrstwfi ) | Positive | 08 Sep 2021 | |
Not Applicable | Maintenance | 106 | aweronfgkn(rquyeafwrz) = 7.3% ajeyazqjec (hoqkopytai ) View more | - | 09 Sep 2019 | ||
Not Applicable | Non-small cell lung cancer stage III First line | - | ldvpieetuc(efqqwogfgg) = yriscekrvy paqfzwwzam (kzogybkjsb ) View more | - | 09 Sep 2019 | ||
Phase 2 | metastatic non-small cell lung cancer First line | 12 | uqphcyyjjt(kmqwzmvxqf) = 42.4% fnltsmwntp (vkufpezvbm ) View more | Positive | 20 May 2012 |